title: Apolipoprotein-defined lipoproteins and apolipoproteins: associations with abnormal albuminuria in type 1 diabetes in the diabetes control and complications trial/epidemiology of diabetes interventions and complications cohort.
abstract: OBJECTIVE
  Dyslipoproteinemia has been associated with nephropathy in diabetes, with stronger correlations in men than in women. We aimed to characterize and compare plasma lipoprotein profiles associated with normal and increased albuminuria in men and women using apolipoprotein-defined lipoprotein subclasses and simple apolipoprotein measures.
  
  
  METHODS
  This is a cross-sectional study in a subset (154 women and 282 men) of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) cohort, using samples obtained in 1997-9. Immunochemical methods were used to quantify plasma apolipoprotein-based lipoprotein subclasses and individual apolipoprotein levels.
  
  
  RESULTS
  In adjusted analyses, elevated Lipoprotein-B (Lp-B) was significantly associated with macroalbuminuria in men [odds ratios (OR) and 95% confidence interval (CI): 2.13 (1.15-3.97)] and women [3.01 (1.11-8.12)], while association with Lp-B:C was observed only in men [1.84 (1.19-2.86)]. For individual apolipoproteins the following significant associations with macroalbuminuria were observed in men only: Apolipoprotein B (ApoB) [1.97 (1.20-3.25)], Apo-AII [0.52 (0.29-0.93)], ApoC-III [1.95 (1.16-3.30)], "ApoC-III in VLDL" (heparin-manganese precipitate) [1.88 (1.16-3.04)], and "ApoCIII in HDL" (heparin-manganese supernatant) [2.03 (1.27-3.26)], all P<0.05).
  
  
  CONCLUSIONS
  Atherogenic apolipoprotein-based profiles are associated with nephropathy in Type 1 diabetic men and to a lesser extent in women. The difference could result from the greater prevalence and severity of dyslipoproteinemia, and from the greater prevalence of renal dysfunction, in men vs women.
authors.affiliation: Harold Hamm Diabetes Center and Section of Endocrinology & Diabetes, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.
authors.forename: Alicia J
authors.initials: AJ
authors.lastname: Jenkins
authors.forename: Jeremy
authors.initials: J
authors.lastname: Yu
authors.forename: Petar
authors.initials: P
authors.lastname: Alaupovic
authors.forename: Arpita
authors.initials: A
authors.lastname: Basu
authors.forename: Richard L
authors.initials: RL
authors.lastname: Klein
authors.forename: Maria
authors.initials: M
authors.lastname: Lopes-Virella
authors.forename: Nathaniel L
authors.initials: NL
authors.lastname: Baker
authors.forename: Kelly J
authors.initials: KJ
authors.lastname: Hunt
authors.forename: Daniel T
authors.initials: DT
authors.lastname: Lackland
authors.forename: W Timothy
authors.initials: WT
authors.lastname: Garvey
authors.forename: Timothy J
authors.initials: TJ
authors.lastname: Lyons
mesh_terms: D000328:Adult; D000419:Albuminuria / Q000097:blood* / Q000453:epidemiology / Q000209:etiology; D001053:Apolipoproteins / Q000097:blood*; D002986:Clinical Trials as Topic; D015331:Cohort Studies; D003430:Cross-Sectional Studies; D003922:Diabetes Mellitus, Type 1 / Q000097:blood* / Q000150:complications / Q000453:epidemiology; D005260:Female; D006801:Humans; D008074:Lipoproteins / Q000097:blood*; D008297:Male; D008875:Middle Aged; D015995:Prevalence
chemical_list: D001053:Apolipoproteins; D008074:Lipoproteins
keywords: Albuminuria; Apolipoproteins; Lipoproteins; Nephropathy; Type 1 diabetes